Immunotherapy articles from across Nature Portfolio

IL-6 blockade represents a promising therapeutic approach for the treatment of osteoarthritis (OA), although durable effects have yet to be explored in clinical trials. Here, the authors report the results of a phase I randomized clinical trial testing the efficacy and safety of PPV-06, an anti-IL-6 active immunotherapy able to modulate the activity of circulating IL-6 in patients with knee OA.

PARP inhibitors, either alone or in combination with bevacizumab, have regulatory approval as maintenance therapy following response to first-line platinum-based chemotherapy. Here this group reports SOLACE2 trial investigating whether combining olaparib with low dose cyclophosphamide treatment improves progression-free survival, comparing to olaparib monotherapy alone, in platinum-sensitive recurrent ovarian cancer.

Peanut oral immunotherapy reshapes T cell responses, suppressing allergy-associated type 2 helper T cells and boosting cytotoxic type 1 helper T cells, offering clues to long-term tolerance.

Polymer-coated liposomes specifically target and deliver interleukin-12 to metastatic ovarian cancer, strongly sensitizing the tumours to combination therapy with immune checkpoint inhibitors.

Huang and colleagues report that TIM4–AMPK signaling induces downregulation of the mitochondrial HSP90 chaperone TRAP1 in tumor-associated macrophages, thereby enhancing their immunoinhibitory function and promoting immune evasion and tumorigenesis.